Propofol
Small molecule targets HOXA11-AS, NOS2, TRPA1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | DIPRIVAN | — | 1991-12-31 – 2001-02-23 | fda.gov ↗ |
| Approved | US (FDA) | DIPRIVAN | — | 1989-10-02 | fda.gov ↗ |
Trials 472 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07294092 | Apr 2026 → Aug 2028 expected | — | Keith M Vogt | Recruiting | No outcome recorded |
| Phase 0 | NCT06626711 | Oct 2024 → Nov 2025 overdue | cancer | Saint Petersburg State University, Russia | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06870357 | Jan → Jun 2024 | — | Second Hospital of Shanxi Medical University | Completed | No outcome recorded |
| Phase 0 | NCT05272202 | Jan 2023 → Dec 2026 expected | — | Brugmann University Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05246371 | Jun → Nov 2021 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT04998253 | Oct → Nov 2020 | COVID-19, acute respiratory distress syndrome | Unidad Temporal COVID-19 en Centro Citibanamex | Completed | No outcome recorded |
| Phase 0 | NCT03498235 | Mar 2018 → Jun 2020 | — | Obstetrics & Gynecology Hospital of Fudan University | Unknown | No outcome recorded |
| Phase 0 | NCT02786329 | Jun 2016 → Aug 2022 | colorectal cancer | Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor | Unknown | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT07198711 | May 2025 → May 2027 expected | — | Stanford University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05742789 | Nov 2021 → Jan 2023 | aortic valve insufficiency, mitral valve insufficiency | Astana Medical University | Completed | No outcome recorded |
| Phase 1 | NCT05695287 | Jan 2021 → Nov 2022 | aortic valve insufficiency, coronary artery disorder, mitral valve insufficiency | Astana Medical University | Completed | No outcome recorded |
| Phase 1 | NCT04680910 | Jan 2021 → Jul 2024 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04062123 | Jul 2020 → Apr 2024 | — | Keith M Vogt | Completed | No outcome recorded |
| Phase 1 | NCT04162535 | Nov 2018 → Dec 2023 | colorectal cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 1 | NCT03362775 | Nov 2018 → Oct 2023 | — | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 1 | NCT03311581 | Sep 2017 → Jun 2021 | end stage renal failure | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02935647 | Oct 2016 → Sep 2018 | major depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT02040909 | Jul 2014 → Jan 2018 | — | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02043977 | Jun 2013 → May 2015 | insomnia, sleep-wake disorder | Life Extension Foundation Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01342328 | May → Nov 2012 | sleep disorder | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 1 | NCT01550770 | Feb → Jul 2012 | — | Ethicon Endo-Surgery | Completed | No outcome recorded |
| Phase 1 | NCT01593397 | Nov 2011 → Sep 2017 | obesity disorder | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01447875 | May 2011 → Dec 2013 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| Phase 1 | NCT01591148 | Jan 2011 → Jul 2017 | morbid obesity | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01191021 | Aug → Oct 2010 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT02229201 | May 2010 → Dec 2013 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 1 | NCT01736020 | Sep 2009 → Apr 2017 | — | Southern California Institute for Research and Education | Unknown | No outcome recorded |
| Phase 1 | NCT00908726 | May 2009 → May 2010 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00826553 | Jan 2009 → Dec 2013 | delirium, respiratory failure | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00142493 | Sep 2004 → Aug 2008 | amnestic disorder | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07672301 | Mar 2026 → Jun 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07086911 | Aug 2025 → Aug 2026 overdue | — | Jinqiao Qian | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06545890 | Aug → Nov 2024 overdue | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03928366 | Jun 2017 → Jan 2019 | codeine toxicity | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1/2 | NCT02050893 | May 2012 → Apr 2013 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06867549 | Mar 2025 → Feb 2028 expected | depressive disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06403852 | May 2024 → Oct 2025 | — | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT05759481 | Feb 2024 → Mar 2025 | — | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05303987 | Oct 2022 → Jan 2027 expected | obstructive sleep apnea syndrome | Erin Kirkham | Recruiting | No outcome recorded |
| Phase 2 | NCT05495945 | Aug 2022 → Oct 2023 | — | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT04790734 | May 2021 → Apr 2022 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT03807297 | Jan → Nov 2019 | — | Rajiv Gandhi Cancer Institute & Research Center, India | Completed | No outcome recorded |
| Phase 2 | NCT04072328 | Oct 2018 → Aug 2020 | — | DongGuk University | Completed | No outcome recorded |
| Phase 2 | NCT03498391 | Jul 2018 → May 2023 | — | University of Pennsylvania | Suspended | No outcome recorded |
| Phase 2 | NCT02839668 | Aug 2016 → Sep 2019 | breast cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2 | NCT02036736 | Apr 2013 → Dec 2014 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT01621373 | Aug 2012 → Jul 2014 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT00228267 | Sep 2004 → Nov 2007 | headache disorder | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT00478907 | Mar 2004 → Mar 2006 | strabismus | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00209521 | Jun 2002 → Jul 2003 | coronary artery disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT06418893 | Aug 2023 → Oct 2024 | — | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| Phase 2/3 | NCT03684447 | Apr 2019 → Dec 2022 | — | University of Utah | Unknown | No outcome recorded |
| Phase 2/3 | NCT03923361 | Apr 2019 → Mar 2024 | — | University of Utah | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02700893 | Mar → Aug 2016 | cerebrovascular disorder | Centre Hospitalier Intercommunal Creteil | Completed | No outcome recorded |
| Phase 2/3 | NCT02393664 | Mar 2015 → Oct 2016 | lung neoplasm | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02105415 | Apr 2014 → Nov 2017 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT01604785 | Nov 2012 → Aug 2016 | migraine disorder | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/3 | NCT01490580 | May 2012 → Aug 2016 | — | Centre Hospitalier Intercommunal Creteil | Completed | No outcome recorded |
| Phase 2/3 | NCT01958138 | Apr → Dec 2012 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 2/3 | NCT01326078 | Jun → Jul 2011 | leukemia | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00734383 | Apr 2005 → May 2012 | myocardial infarction | University of British Columbia | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT07627906 | Jul → Dec 2026 expected | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07530146 | May → Aug 2026 overdue | infectious disease with sepsis, pneumonia | Helwan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07303985 | Dec 2025 → Feb 2026 | — | Jun Zhang | Completed | No outcome recorded |
| Phase 3 | NCT06733129 | Apr 2025 → Apr 2027 expected | — | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07019805 | Sep 2024 → Mar 2025 | acute hypotension | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT05615025 | Jan → Jun 2023 | neuromuscular junction disease | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05358535 | Sep 2022 → Jan 2027 expected | — | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05263674 | Feb 2022 → Dec 2027 expected | epilepsy | University of Southern Denmark | Recruiting | No outcome recorded |
| Phase 3 | NCT03841812 | Jan → Jun 2020 | — | China International Neuroscience Institution | Completed | No outcome recorded |
| Phase 3 | NCT05696509 | Jan 2020 → Oct 2022 | aortic valve insufficiency, mitral valve insufficiency | Astana Medical University | Completed | No outcome recorded |
| Phase 3 | NCT04016246 | Oct 2019 → Mar 2024 | respiratory distress syndrome in premature infants | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 3 | NCT02734511 | May 2017 → Sep 2019 | — | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 3 | NCT03022240 | Jan 2017 → Sep 2019 | — | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT04486690 | Jul 2016 → Jun 2017 | — | ghada fouad | Completed | No outcome recorded |
| Phase 3 | NCT02492282 | Jun → Dec 2015 | — | Universidad de Antioquia | Completed | No outcome recorded |
| Phase 3 | NCT01856998 | May 2013 → Feb 2014 | — | Fresenius Kabi | Completed | No outcome recorded |
| Phase 3 | NCT01387139 | Jan 2011 → Jan 2014 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT02046720 | Jun 2010 → Nov 2013 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 3 | NCT00741949 | Sep 2008 → Jun 2011 | acute respiratory failure | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00690495 | May → Sep 2008 | — | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 3 | NCT01242241 | Apr 2008 → Dec 2011 | obesity disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00741351 | Dec 2007 → Mar 2009 | — | Azienda Ospedaliera San Gerardo di Monza | Completed | No outcome recorded |
| Phase 3 | NCT00506246 | Jun → Oct 2007 | — | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 3 | NCT00559468 | Dec 2006 → Mar 2007 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00389883 | Nov 2006 → Jan 2010 | supratentorial cancer | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00405522 | Nov 2006 → Jun 2007 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00336882 | Jun 2006 → Oct 2009 | traumatic brain injury | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00219856 | Aug 2004 → Mar 2006 | — | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00192959 | Mar → Dec 2004 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT00287560 | Aug 2003 → Feb 2005 | — | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 4165 trials | ||||||
| Phase 4 | NCT07653867 | Nov 2026 → Jun 2028 expected | — | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07637279 | Nov 2026 → Jun 2028 expected | polyp of large intestine | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644663 | Jun → Aug 2026 overdue | — | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07601698 | May → Nov 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07334132 | Apr 2026 → Dec 2029 expected | osteoarthritis | Region Örebro County | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07556523 | Mar 2026 → Apr 2028 expected | aortic valve stenosis | David Lyubashevsky | Recruiting | No outcome recorded |
| Phase 4 | NCT07347496 | Mar 2026 → May 2028 expected | — | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07103616 | Sep 2025 → Sep 2028 expected | local anesthetic poisoning | Children's Hospital Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07161518 | Sep 2025 → Aug 2027 expected | — | Stanford University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06763705 | Jun → Dec 2025 | — | Qassim Health Cluster | Completed | No outcome recorded |
| Show all 165 trials opens the full record — a long page | ||||||
| Phase not applicable216 trials | ||||||
| — | NCT07678216 | Jul 2026 → Jun 2028 expected | traumatic brain injury | Aswan University | Not yet recruiting | No outcome recorded |
| — | NCT07460050 | Mar → Aug 2026 overdue | — | Hayatabad Medical Complex | Not yet recruiting | No outcome recorded |
| — | NCT07534956 | Jan 2026 → Oct 2027 expected | — | Marmara University Pendik Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07325669 | Jan 2026 → Jan 2027 expected | — | dilara gocmen | Not yet recruiting | No outcome recorded |
| — | NCT07304206 | Dec 2025 → Feb 2026 | — | Inonu University | Completed | No outcome recorded |
| — | NCT07271472 | Dec 2025 → May 2026 | — | Ataturk University | Completed | No outcome recorded |
| — | NCT07204106 | Oct → Nov 2025 | — | Shiyou Wei | Completed | No outcome recorded |
| — | NCT07166640 | Sep → Oct 2025 | — | Kocaeli City Hospital | Completed | No outcome recorded |
| — | NCT07162805 | Sep → Oct 2025 | — | Kocaeli City Hospital | Completed | No outcome recorded |
| — | NCT06907823 | Jun → Dec 2025 overdue | — | Pusan National University Yangsan Hospital | Not yet recruiting | No outcome recorded |
| Show all 216 trials opens the full record — a long page | ||||||
Also used as a comparator or background therapy in 945 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 018 trials | ||||||
| Phase 0 | NCT07247968 Background | Nov 2025 → Nov 2026 expected | depressive disorder | Min Su | Recruiting | No outcome recorded |
| Phase 0 | NCT06756178 Comparator | Jan 2025 → Nov 2026 expected | delirium | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06717945 Comparator | Jan → May 2025 overdue | — | Chinese Academy of Medical Sciences, Fuwai Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06561672 Background | Sep 2024 → Mar 2025 overdue | — | Zagazig University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06368219 Comparator | Apr → Sep 2024 | — | Alexandria University | Unknown | No outcome recorded |
| Phase 0 | NCT06720285 Background | Oct → Nov 2023 | — | Universitas Airlangga | Completed | No outcome recorded |
| Phase 0 | NCT05993039 Comparator | Sep 2023 → Dec 2024 | auditory system disorder | Our Lady of the Lake Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05880459 Comparator | Aug 2023 → Nov 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT05486819 Comparator | Aug 2022 → Feb 2023 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT05266560 Comparator | Mar 2022 → Jul 2024 | depressive disorder | First Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT04992572 Comparator | Dec 2021 → Dec 2026 expected | lumbar spinal stenosis | Stanford University | Recruiting | No outcome recorded |
| Phase 0 | NCT04777110 Background | Aug 2021 → Aug 2022 | depressive disorder | First Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT06661005 Comparator | May → Sep 2021 | — | University of Arizona | Terminated | No outcome recorded |
| Phase 0 | NCT04337073 Comparator | Sep → Oct 2020 | — | Yangzhou University | Completed | No outcome recorded |
| Phase 0 | NCT04142840 Comparator | Nov 2019 → Aug 2021 | — | RenJi Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04016740 Background | Aug 2019 → Feb 2020 | coronary artery disorder, delirium | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04018157 Comparator | Jul → Nov 2019 | — | Zagazig University | Completed | No outcome recorded |
| Phase 0 | NCT02972762 Comparator | Nov 2016 → Dec 2018 | avascular necrosis | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT07603596 Background | May 2026 → Apr 2028 expected | delirium, digestive system neoplasm | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06644573 Background | Nov 2025 → May 2026 overdue | Alzheimer disease, Parkinson disease, REM sleep behavior disorder, anxiety +6 | Nyree Penn | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07669012 Comparator | Oct 2025 → Oct 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 1 | NCT06129188 Comparator | Feb → Nov 2025 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1 | NCT05591001 Comparator | Oct 2022 → Mar 2023 | tethered spinal cord syndrome | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT07404306 Comparator | Aug 2022 → Oct 2023 | — | Haisco-USA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05614544 Comparator | Aug 2022 → Oct 2023 | — | Haisco-USA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05025397 Background | Sep 2021 → Mar 2022 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05536362 Background | Feb 2021 → Jan 2022 | colon carcinoma | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT04678050 Comparator | Oct 2020 → Dec 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT04294056 Comparator | May → Jun 2020 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03745625 Comparator | Jan → Jul 2019 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06867068 Comparator | Oct 2016 → Jun 2024 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02571426 Comparator | Oct 2015 → Mar 2018 | kidney failure | Uppsala University | Completed | No outcome recorded |
| Phase 1 | NCT04037657 Comparator | Apr → Jun 2015 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04033939 Comparator | Apr → Nov 2014 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01640275 Comparator | Mar 2012 → Mar 2015 | — | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT01308541 Comparator | Jan → Aug 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01309984 Comparator | Nov 2010 → Oct 2012 | lactation disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00894751 Comparator | Jan 2009 → Jan 2011 | — | Children's Hospital Medical Center, Cincinnati | Terminated | No outcome recorded |
| Phase 1 | NCT02188407 Comparator | Jul 2008 → Sep 2013 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 1 | NCT00683956 Background | May 2008 → Jul 2009 | — | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT00671931 Comparator | Apr 2007 → Jan 2009 | scoliosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT04686448 Comparator | Jan → Apr 2021 | — | Zagazig University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04621526 Comparator | Nov 2020 → Aug 2023 | — | Zagazig University | Completed | No outcome recorded |
| Phase 1/2 | NCT04220281 Comparator | Dec 2019 → Feb 2020 | — | Ain Shams University | Terminated | No outcome recorded |
| Phase 1/2 | NCT03610282 Background | Nov 2019 → Nov 2020 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02918877 Comparator | Jun 2017 → Dec 2018 | acute lung injury | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02429076 Background | Jun 2017 → Jul 2019 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02065947 Comparator | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01318044 Comparator | Jan → Apr 2011 | — | University Clinical Centre of Kosova | Unknown | No outcome recorded |
| Phase 1/2 | NCT01216007 Comparator | Oct 2010 → Oct 2012 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 1/2 | NCT01342835 Comparator | Sep 2010 → Jan 2011 | — | University Clinical Centre of Kosova | Unknown | No outcome recorded |
| Phase 1/2 | NCT00538616 Comparator | Jan → Feb 2008 | brain injury | Carmelo Graffagnino | Completed | No outcome recorded |
| Phase 1/2 | NCT00484575 Comparator | Jun 2007 → Oct 2008 | atrial fibrillation, myocardial disorder | Karolinska Institutet | Completed | No outcome recorded |
| Phase 250 trials | ||||||
| Phase 2 | NCT07705022 Background | Jul 2026 → Jan 2028 expected | — | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07479550 Background | Jul 2026 → Jul 2027 expected | major depressive disorder | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03643367 Comparator | Jan 2026 → Feb 2027 expected | — | University of Zurich | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06744361 Comparator | Dec 2024 → Sep 2027 expected | cardiac arrest | Christian Hassager | Recruiting | No outcome recorded |
| Phase 2 | NCT06096181 Comparator | Dec 2023 → Dec 2024 | adolescent idiopathic scoliosis | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT06034873 Comparator | Nov 2023 → Sep 2025 | — | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT05870514 Comparator | Jun 2023 → Mar 2024 | — | Xiaobo Yang, MD | Unknown | No outcome recorded |
| Phase 2 | NCT06017141 Background | May 2023 → May 2025 | colon adenocarcinoma | University of Kansas Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05152303 Background | Oct 2022 → Apr 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05539521 Comparator | Sep 2022 → Feb 2023 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT05491278 Comparator | Aug 2022 → Jun 2023 | critical illness polyneuropathy | Xiaobo Yang, MD | Completed | No outcome recorded |
| Phase 2 | NCT05635955 Comparator | Aug → Sep 2022 | — | Maternal and Child Health Hospital of Hubei Province | Completed | No outcome recorded |
| Phase 2 | NCT05092152 Comparator | Oct 2021 → Oct 2023 | acute respiratory failure | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT05015361 Comparator | May → Jun 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04669821 Comparator | Mar → Aug 2021 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05502458 Comparator | Dec 2020 → Aug 2022 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04467424 Background | Jun → Nov 2020 | — | University Hospital of Split | Completed | No outcome recorded |
| Phase 2 | NCT04048811 Comparator | Dec 2019 → May 2020 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04147416 Comparator | Nov 2019 → May 2020 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03933280 Comparator | Jul 2019 → Dec 2020 | — | Menoufia University | Completed | No outcome recorded |
| Phase 2 | NCT03925779 Comparator | Jun 2019 → Dec 2020 | — | Menoufia University | Completed | No outcome recorded |
| Phase 2 | NCT03854812 Comparator | Mar → Oct 2019 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03448068 Background | Apr 2018 → Jan 2020 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03548493 Background | Apr → Aug 2018 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03709056 Comparator | Dec 2017 → Feb 2018 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03698617 Comparator | Dec 2016 → Jun 2018 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03773042 Comparator | Dec 2016 → Jun 2017 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02884440 Background | Nov 2016 → May 2019 | spondylolisthesis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03003884 Comparator | Nov 2016 → Mar 2017 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02877238 Comparator | Aug 2016 → May 2017 | congenital heart disease | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02727621 Comparator | Apr → Sep 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02946437 Comparator | Nov 2015 → Dec 2019 | acquired aneurysmal subarachnoid hemorrhage | University of Zurich | Withdrawn | No outcome recorded |
| Phase 2 | NCT02554253 Comparator | Sep 2015 → Dec 2020 | acute kidney injury, delirium | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02618668 Comparator | Jul 2015 → Jul 2018 | cholangitis, pancreatitis | Assiut University | Terminated | No outcome recorded |
| Phase 2 | NCT02651792 Comparator | Jan 2015 → Apr 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02282891 Comparator | Jan 2015 → Jan 2016 | — | Yale University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02406872 Comparator | Dec 2014 → Aug 2015 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03231683 Comparator | Mar 2014 → May 2016 | — | KK Women's and Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01937767 Comparator | Aug 2013 → Feb 2014 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01948765 Comparator | Jun 2013 → Sep 2014 | coronary artery disorder | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT01691690 Background | Oct 2012 → Nov 2015 | tonsillitis | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01516684 Background | May 2012 → Jun 2018 | cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01505933 Comparator | Feb 2012 → Dec 2017 | — | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01567657 Comparator | Jan 2012 → Jan 2013 | hypotensive disorder | Kantonsspital Münsterlingen | Completed | No outcome recorded |
| Phase 2 | NCT01369147 Background | Jul 2011 → Dec 2014 | — | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01189604 Comparator | Aug → Nov 2010 | gastrointestinal polyp | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01007773 Background | Jan 2010 → Jan 2011 | traumatic brain injury | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 2 | NCT00390871 Comparator | May 2005 → Dec 2007 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00695214 Background | Feb 2004 → Jun 2035 expected | obstructive sleep apnea syndrome | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT01140100 Comparator | — | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/315 trials | ||||||
| Phase 2/3 | NCT07036419 Comparator | Jul 2025 → May 2026 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT06427707 Comparator | Jun → Oct 2024 overdue | esophageal varices with bleeding | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06131905 Comparator | Jan 2024 → Jan 2025 | magnesium deficiency | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06014138 Comparator | Nov 2023 → Jul 2027 expected | acute respiratory distress syndrome | Guy's and St Thomas' NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05032118 Comparator | Apr 2023 | acquired aneurysmal subarachnoid hemorrhage | Jenna L Leclerc MD, PhD | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT06756971 Comparator | Jun 2022 → Nov 2023 | sleep apnea syndrome | University of Iowa | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05636566 Comparator | Feb → Sep 2022 | childhood malignant neoplasm, invasive carcinoma | Alexandria University | Completed | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 2/3 | NCT03285165 Comparator | Sep 2017 → Sep 2021 | — | Assiut University | Suspended | No outcome recorded |
| Phase 2/3 | NCT03115489 Comparator | May 2017 → Dec 2019 | epilepsy | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03143933 Comparator | Jul 2016 → Jul 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02606409 Comparator | Nov 2015 → Jun 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02203175 Comparator | Apr 2011 → Apr 2012 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01279499 Comparator | Apr 2010 → Jun 2011 | morbid obesity | University of Patras | Unknown | No outcome recorded |
| Phase 2/3 | NCT00815893 Comparator | Aug 2008 → Aug 2009 | — | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| Phase 388 trials | ||||||
| Phase 3 | NCT07510945 Comparator | May 2026 → May 2028 expected | — | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07269808 Comparator | Mar → Jul 2026 overdue | — | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07414706 Background | Mar 2026 → Jun 2028 expected | local anesthetic poisoning | Centre Hospitalier Universitaire, Amiens | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07299630 Background | Dec 2025 → May 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT07116733 Comparator | Oct 2025 → Dec 2028 expected | — | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07099014 Comparator | Sep 2025 → Oct 2028 expected | cardiogenic shock | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07596589 Comparator | Apr 2025 → Jan 2027 expected | — | Southeast University, China | Recruiting | No outcome recorded |
| Phase 3 | NCT06714669 Comparator | Jun → Oct 2024 | — | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT06271174 Background | Jun 2024 → Jun 2026 | — | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT06391931 Comparator | Apr → Nov 2024 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06222294 Comparator | Mar → Aug 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05486416 Comparator | Jan → Jul 2024 | — | Haisco-USA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06188546 Comparator | Jan 2024 → Jan 2025 | — | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT06013345 Comparator | Oct 2023 → Sep 2024 | atrial fibrillation | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 3 | NCT05849779 Comparator | Jul 2023 → May 2026 overdue | acute respiratory distress syndrome | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 3 | NCT05839366 Comparator | May 2023 → Oct 2024 | infectious disease with sepsis | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05555667 Comparator | May 2023 → Nov 2025 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT05782894 Comparator | Feb → Nov 2023 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT05635201 Comparator | Dec 2022 → Sep 2023 | — | Daegu Catholic University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05478174 Comparator | Jul 2022 → Nov 2023 | — | Haisco-USA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05327296 Comparator | Jun 2022 → May 2024 | — | Sedana Medical | Completed | No outcome recorded |
| Phase 3 | NCT05346666 Background | Jun 2022 → Sep 2023 | epilepsy | Damanhour University | Unknown | No outcome recorded |
| Phase 3 | NCT05312385 Comparator | Apr 2022 → Apr 2024 | — | Sedana Medical | Completed | No outcome recorded |
| Phase 3 | NCT06809218 Comparator | Apr 2022 → Nov 2024 overdue | — | Sedana Medical | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05444751 Background | Mar 2022 → Sep 2026 expected | lumbar disk disease, radiculopathy | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05259631 Comparator | Mar 2022 → Feb 2025 | adult acute respiratory distress syndrome | Negovsky Reanimatology Research Institute | Suspended | No outcome recorded |
| Phase 3 | NCT05849597 Comparator | Mar 2022 → Feb 2025 overdue | delirium | University of Novi Sad | Recruiting | No outcome recorded |
| Phase 3 | NCT05958589 Background | Jan 2022 → Jul 2024 | — | University of Novi Sad | Completed | No outcome recorded |
| Phase 3 | NCT04947345 Comparator | Sep 2021 → Mar 2022 | — | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04958746 Comparator | Jul → Sep 2021 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04711837 Comparator | Feb 2021 → Apr 2022 | — | Haisco-USA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04620031 Comparator | Dec 2020 → Jun 2021 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04511728 Comparator | Nov → Dec 2020 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04530188 Comparator | Nov 2020 → May 2022 | acute respiratory distress syndrome | Bicetre Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04513808 Comparator | Aug 2020 → Dec 2025 overdue | esophageal cancer | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 3 | NCT04341350 Comparator | Aug 2020 → Sep 2025 overdue | — | University Hospital, Brest | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04316013 Comparator | Jul 2020 → Feb 2025 | colon carcinoma, non-small cell lung carcinoma, rectal carcinoma | Peter MacCallum Cancer Centre, Australia | Terminated | No outcome recorded |
| Phase 3 | NCT04400201 Comparator | Jun → Oct 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04235608 Comparator | May 2020 → Oct 2023 | acute respiratory distress syndrome | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 3 | NCT04355962 Comparator | Apr 2020 → Jun 2021 | COVID-19, acute respiratory distress syndrome | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT04197570 Comparator | Feb → Mar 2020 | substance-related disorder | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT04081545 Comparator | Dec 2019 → Mar 2023 | substance-related disorder | Christine Oryhan | Completed | No outcome recorded |
| Phase 3 | NCT04111159 Comparator | Dec 2019 → Jun 2020 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03825198 Comparator | Aug 2019 → Dec 2023 | neuropathy, painful, peripheral nerve lesion | Dr M. B. Breebaart | Unknown | No outcome recorded |
| Phase 3 | NCT03921775 Comparator | May → Dec 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03808844 Comparator | Mar → Aug 2019 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03653832 Comparator | Dec 2018 → Dec 2023 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT03674008 Comparator | Oct 2018 → Jan 2019 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03661489 Comparator | Jul 2018 → Apr 2020 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03779061 Comparator | Jun → Sep 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01519154 Comparator | Feb 2018 → Jun 2024 | — | Achim Schmitz | Completed | No outcome recorded |
| Phase 3 | NCT03434678 Background | Jan 2018 → Jul 2024 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT04034771 Background | Jan → Apr 2018 | traumatic brain injury | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03425474 Comparator | Sep → Nov 2017 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03669484 Comparator | Aug 2017 → May 2018 | — | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT02822144 Background | Sep 2016 → Aug 2020 | stroke disorder | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02740127 Background | Jun 2016 → May 2020 | male reproductive organ cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT03388151 Comparator | Apr 2016 → Nov 2022 | cirrhosis of liver | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT03466632 Comparator | Apr 2016 → Apr 2020 | colonic disorder | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02634255 Background | Dec 2015 → May 2016 | appendicitis | Diskapi Yildirim Beyazit Education and Research Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02481791 Background | Jul 2015 → Dec 2019 | heart disorder | Alder Hey Children's NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT02523859 Comparator | Jul 2015 → Mar 2016 | — | Paion UK Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02322502 Comparator | Feb 2015 → Feb 2016 | — | RWTH Aachen University | Completed | No outcome recorded |
| Phase 3 | NCT02079090 Background | Jul 2014 → Jun 2017 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT04686058 Comparator | Mar → Dec 2014 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT02455440 Comparator | Mar 2014 → Jul 2015 | brain aneurysm | George Papanicolaou Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03764267 Comparator | Jan 2014 → Jan 2017 | breast disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT01994070 Comparator | Nov 2013 → Mar 2015 | atrial fibrillation | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT01961349 Comparator | Oct 2013 → Mar 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01739933 Comparator | May 2013 → Jul 2019 | delirium, infectious disease with sepsis | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01248234 Comparator | Jul 2012 | hypertensive disorder | University of Mississippi Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT01565590 Comparator | Feb 2012 → Jul 2015 | acquired aneurysmal subarachnoid hemorrhage | University of Cincinnati | Terminated | No outcome recorded |
| Phase 3 | NCT01152021 Comparator | Aug 2011 → Jul 2014 | — | Boston Children's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT01294163 Comparator | Apr 2011 → Apr 2014 | coronary artery disorder, drug allergy | Air Liquide | Completed | No outcome recorded |
| Phase 3 | NCT01211158 Comparator | Dec 2010 → Sep 2011 | — | Lions Gate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01222169 Background | Sep 2010 → May 2012 | laryngeal disorder | Thomas Erb | Completed | No outcome recorded |
| Phase 3 | NCT01006668 Comparator | Nov 2009 → Nov 2014 | — | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 3 | NCT00848991 Comparator | Feb 2009 → Feb 2010 | — | The Cooper Health System | Completed | No outcome recorded |
| Phase 3 | NCT01858090 Comparator | Jan → Oct 2009 | — | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00436345 Comparator | Nov 2007 → Aug 2008 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT00542542 Comparator | Sep 2007 → Mar 2014 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00479661 Comparator | May 2007 → Mar 2010 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00418457 Comparator | Jan 2007 → Feb 2018 | breast neoplasm | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00337051 Comparator | Jun 2006 → Feb 2010 | acute kidney injury, end stage renal failure | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00265616 Comparator | May 2006 → Mar 2010 | — | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00984633 Background | Jun → Dec 2003 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00988520 Background | May → Sep 2003 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00187135 Comparator | Mar 2002 → Aug 2008 | bone marrow disorder | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 4339 trials | ||||||
| Phase 4 | NCT07597109 Background | Sep 2026 expected | arterial disorder | Insel Gruppe AG, University Hospital Bern | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07665151 Background | Jul → Aug 2026 overdue | — | Shiyou Wei | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07678411 Background | Jul 2026 overdue | upper digestive tract disorder | Shiyou Wei | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07670923 Comparator | Jul 2026 → Feb 2027 expected | — | General Hospital of Ningxia Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07696208 Comparator | Jul 2026 → Jan 2028 expected | ischemic stroke | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Show all 339 trials opens the full record — a long page | ||||||
| Phase not applicable400 trials | ||||||
| — | NCT07486336 Comparator | Sep 2026 → Sep 2028 expected | cognitive disorder | Ente Ospedaliero Ospedali Galliera | Not yet recruiting | No outcome recorded |
| — | NCT06727435 Background | Aug 2026 → Apr 2028 expected | — | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07680400 Background | Jul → Aug 2026 overdue | — | Bezmialem Vakif University | Not yet recruiting | No outcome recorded |
| — | NCT07699523 Background | Jun 2026 → Jun 2027 expected | electroencephalographic peculiarity: fronto-precentral beta wave groups | China-Japan Friendship Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07674719 Comparator | Jun 2026 → Jun 2027 expected | acute kidney injury | Seoul National University Bundang Hospital | Not yet recruiting | No outcome recorded |
| Show all 400 trials opens the full record — a long page | ||||||
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 1,419 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | propofol | “Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the...” NCT06029049 ↗1413“Eighty females (20-65 years old) undergoing thyroid surgery were prospectively recruited and randomized to either the TIVA (effect-site target controlled infusion using...” PMID 25500679 ↗ Dec 2014 “This project is based on a previous randomized, double blind prospective trial (conducted by one of these authors and not yet published) comparing two groups of patients who...” NCT04005599 ↗ “1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine...” NCT03176758 ↗ “Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg,Cisatracurium 0.15 mg/kg,propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2...” NCT07019246 ↗ “The investigators will not mandate the sedative type, but rather encourage the use of sedatives that are already routinely used in participating ICUs (typically a...” NCT05849779 ↗ “Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal...” NCT05897151 ↗ “In the TIVA group (total intravenous anaesthesia group), induction and maintenance of anaesthesia will be performed using target-controlled infusion (TCI) with propofol...” NCT07325669 ↗ “High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic...” NCT05263674 ↗ “Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle...” NCT05958589 ↗ “Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation or high-flow nasal cannula oxygen therapy (if...” NCT05718024 ↗ “During the total intravenous anesthesia (TIVA) with propofol and remifentanil, prior administration of remifentanil could reduce the propofol infusion pain without other...” NCT01030510 ↗ “Standard anaesthesia with propofol with co-administration of Dexmedetomidine and Propofol with Dexmedetomidine (bolus 0.4 mcg/kg over 10 minutes followed by an continuous...” NCT07597109 ↗ “In the TIVA (Total Intra Venous Anesthesia) group, a combination of propofol (50-150 μg/kg/min) and remifentanil (0.02-0.2 μg/kg/min) was used for general anesthesia instead of...” NCT06558695 ↗ “Anesthesia induction was performed using propofol and remifentanil, followed by maintenance with sevoflurane to ensure adequate anesthetic depth and hemodynamic stability...” NCT07097220 ↗ “Propofol is a short-acting intravenous sedative agent used for the induction of general anesthesia for children and adults; maintenance of general anesthesia; and sedation in...” NCT00789815 ↗ “In Group K, ketamine-propofol will be prepared in a 1:1 ratio (both 10 mg/mL) in the same syringe, while in Group F, fentanyl (1-2 mcg/kg) and propofol (1 mg/kg) will be...” NCT06412861 ↗ “anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values...” NCT01304953 ↗ “Intervention (if applicable): Patients will be randomised into two groups, one group will be given 200 milligrams of Propofol and the other group will be given 350 milligrams...” NCT00395681 ↗ “Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC.” NCT05444751 ↗ “Pediatric patients who are planned to undergo an MRI scan with generalized anesthesia will be randomized to either IV anesthesia with propofol or inhalation anesthesia with sevoflurane.” NCT06876870 ↗ “In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl” NCT05485480 ↗ “Loading dose: 0.08mg/kg, Drug: Propofol Injection Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.2mg/kg/h IV of Propofol Injection” NCT05152303 ↗ “Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion” NCT03129009 ↗ “Intrathecal hyperbaric bupivacaine (0.5%) and a mixture of propofol (1-2 mg/kg) and fentanyl (50-100 μg/kg) were used as induction agents in the SA and GA groups, respectively” PMID 39740955 ↗ Apr 2026 “General anaesthesia is provided using total intravenous anaesthesia with short-acting agents, primarily propofol and remifentanil, administered by trained anaesthesiologists.” NCT07334132 ↗ “Use of a hypnotic("propofol 2.5mg/kg"), morphine("remifentanil1yg/kg") and curare("atracurium0.5mg/kg"), with the support of orotracheal intubation and mechanical ventilation” NCT03666949 ↗ “If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).” NCT02219659 ↗ “General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).” NCT04294537 ↗ “Intravenous Induction of Anesthesia Using a Mixture of Ketamine and Propofol in a ratio of 1:1 in elderly patients given in a dose of 1 mg/kg ketamine and 1 mg/kg propofol” NCT07002073 ↗ “general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.” NCT03569046 ↗ “Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.” NCT04095754 ↗ “Esketamine and propofol will be prepared shortly before injection by the nurse anesthetist as follows: 4 ml esketamine 25mg/ml, 6ml NaCl (0,9%), 10ml propofol (10mg/ml).” NCT05655754 ↗ “with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h.” NCT03437213 ↗ “Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.” NCT05019222 ↗ “Total IntraVenous Anesthesia - to achieve deep-sedation via chemical analgesic (propofol, dexmedetomidine, fentanyl, hydromorphone); continuous intravenous infusion.” NCT07672301 ↗ “Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia.” NCT04310748 ↗ “may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion” NCT03263117 ↗ “Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).” NCT03239236 ↗ “This is a single-center, prospective, randomized, controlled pilot study using remimazolam and propofol for sedation in mechanically ventilated ICU patients.” NCT04790734 ↗ “TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness.” NCT06120439 ↗ “1. experimental group The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn.” NCT07247968 ↗ “Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.” NCT00757458 ↗ “Anesthetic agents, including propofol, fentanyl, rocuronium, and sevoflurane, were used as part of standard anesthetic management during the procedure.” NCT07370779 ↗ “Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.” NCT04994704 ↗ “The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗ “Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)” NCT04281017 ↗ “Standardized general anaesthesia with fentanyl 2 mcg/kg ABW at induction, propofol 1.5 mg/kg, rocuronium 0.6 mg/kg, sevoflurane 1 MAC for maintenance” NCT07299630 ↗ “General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane.” NCT06584695 ↗ “Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.” NCT04998253 ↗ “Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients” NCT05473949 ↗ “Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min) given intravenously” NCT05706844 ↗ “Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mcg/kg/min) and fentanyl infusion (1-2mcg /kg/hour)” NCT06613893 ↗ “propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.” NCT04390698 ↗ “Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment.” NCT05786833 ↗ “Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response.” NCT02768376 ↗ “Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.” NCT03962725 ↗ “TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.” NCT01833715 ↗ “Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively” NCT02786329 ↗ “intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)” NCT02664142 ↗ “Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds.” NCT05509192 ↗ “Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.” NCT05632159 ↗ “Deep sedation(Propofol Injectable Emulsion or Midazolam Injection) combined with intermittent bolus injection of muscle relaxants is used” NCT05658692 ↗ “Ketofol, a mixture of ketamine and propofol, has been used in different favorable recovery profiles regarding postoperative EA and PONV.” NCT06010927 ↗ “The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn.” NCT04777110 ↗ “In the Total i.v. anaesthesia (TIVA) group (n=60), patients underwent opioid-free TIVA with propofol, ketamine, and dexmedetomidine.” PMID 24554545 ↗ Feb 2014 “Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine” NCT04355962 ↗ “remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60 (Group R)” NCT02712528 ↗ “The traditional treatment for refractory status epilepticus includes diazepam, midazolam, valproic acid, thiopental and propofol.” NCT03115489 ↗ “Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.” NCT00913861 ↗ “Ketofol which is a mixture of ketamine and propofol gains increasing interest as an agent for procedural sedation and analgesia” NCT04816162 ↗ “Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).” NCT02217319 ↗ “In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.” NCT02813044 ↗ “Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation” NCT05417529 ↗ “were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction.” NCT05550714 ↗ “Anesthesia induction will include 2 mg midazolam, 2-2.5 mg/kg propofol, 0.6-0.9 mg/kg rocuronium, and 1 μg/kg remifentanil.” NCT07271472 ↗ “Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium.” NCT03157479 ↗ “The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.” NCT02039453 ↗ “Ketofol will be prepared by adding 40 mg of ketamine to 160 mg of propofol and diluted to 20 ml with normal saline 0.9%.” NCT06545890 ↗ “followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the surgery” NCT07062601 ↗ “Pharmacodynamic Effects of Propofol and Alfentanil on EEG During Endoscopic Retrograde Cholangiopancreatography (ERCP)” NCT07211828 ↗ “Remifentanil and propofol will be delivered intravenously via TCI pumps according to the "Marsh" and "Minto" algorithm” NCT01733472 ↗ “In the Ketofol group, 2 ml ketamine (50mg/ml) and 10 ml of propofol 1% (10mg/ml) were diluted in 8ml of normal saline.” NCT06212401 ↗ “In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion.” NCT05951842 ↗ “Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled.” NCT00826553 ↗ “The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).” NCT02659228 ↗ “Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection” NCT02123355 ↗ “GA will be induced with midazolam 1-2 mg, fentanyl 2μ/kg and propofol titrated to achieve loss of consciousness.” NCT03013075 ↗ “general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium” NCT06202664 ↗ “patients in group C will receive fentanyl 1 μg/kg, propofol 2.5 mg/kg, and rocuronium 0.3 mg/kg intravenously” NCT07680400 ↗ “Sevoflurane and propofol are widely used for the maintenance of general anesthesia during bariatric surgery.” NCT03946657 ↗ “All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.” NCT02399397 ↗ “lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly” NCT05577962 ↗ “Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant” NCT06044103 ↗ “The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane.” NCT02058511 ↗ “The TCI group included patients who received a total intravenous anesthesia with propofol and remifentanil.” PMID 27549313 ↗ Aug 2016 “one under complete intravenous anesthesia (infusion of Propofol, Ketamine, Lignocaine and Dexmedetomidine)” NCT06390046 ↗ “Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride” NCT04144153 ↗ “General anesthesia with Lidocaine 1.5mg/kg, Fentanyl 2 mcg/kg, propofol 2 mg/kg, Rocuronium 0.6 mg/kg” NCT06892600 ↗ “During surgery an infusion of propofol (0.8-2.5 mg/min) is used to induce a light level of sedation.” NCT01604382 ↗ “General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance.” NCT03012945 ↗ “After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered.” NCT03467750 ↗ “Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning” NCT02877238 ↗ “Rescue hypnotic sedation with midazolam or propofol is permitted for safety and clinical necessity.” NCT06727435 ↗ “Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration” NCT02505880 ↗ “General anesthesia using classical GABAergic-drugs such as propofol, remifentanil and rocuronium.” NCT07486336 ↗ “Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg” NCT03367988 ↗ “Included patients randomized in control group, intravenouse sedation is continued with propofol” NCT03643367 ↗ “Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact” NCT04727515 ↗ “Propofol is one of the most widely used anesthetics for its fast onset and quick elimination.” NCT04595591 ↗ “Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol” NCT01934049 ↗ “Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol.” NCT06661005 ↗ “Short-acting anesthetics, such as propofol and remifentanil might favor this objective.” PMID 23774117 ↗ Jan 2014 “Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam.” NCT02534012 ↗ “Patient controlled propofol sedation. 5 mg propofol iv per push. Max 8 pushes/minute” NCT07637279 ↗ “All patients will receive general anesthesia induction by propofol 1.5-2 mg/kg (LBW)” NCT06343753 ↗ “In group B: propofol 1.5 mg/kg and fentanyl 2 µg/kg were administered intravenously.” NCT05019560 ↗ “Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary” NCT02884440 ↗ “General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min)” NCT03081897 ↗ “Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).” NCT04473846 ↗ “0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).” NCT02079090 ↗ “The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.” NCT03864016 ↗ “Patients will receive Ketofol (propofol- ketamine mixture in a ratio of 1:1).” NCT07627906 ↗ “Propofol, Atracurium Besilate or Cisatracurium besylate or Rocuronium Bromide” NCT04553536 ↗ “Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).” NCT02289391 ↗ “anesthesia was induced by slow intravenous injection of propofol (1-2 mg/kg)” NCT05148637 ↗ “ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min)” NCT03764267 ↗ “Intravenous sedation using propofol or dexmedetomidine will be administered.” NCT03404180 ↗ “Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1)” NCT02355678 ↗ “Total intravenous anesthesia with propofol for maintenance of anesthesia.” NCT04976842 ↗ “propofol 2mg/kg , atracurium0.5ml/kg ,fentanyl 100 microgram in induction” NCT03422354 ↗ “Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium” NCT05172739 ↗ “Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml” NCT00854178 ↗ “followed by intravenous injection of propofol (2 mg/kg) for 30 seconds” NCT06172140 ↗ “Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion” NCT03778723 ↗ “a first continuous parenteral sedative agent (midazolam or propofol)” NCT06549426 ↗ “Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia” NCT05380778 ↗ “Patients undergo standard anesthesia (remifentanil with propofol)” NCT01404819 ↗ “All patients receive 2.5 mg/kg propofol injected over 30 seconds.” NCT07581665 ↗ “Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV” NCT03448068 ↗ “Step 2: Propofol infusion (with a maximum rate of 8 mg/kg/hour)” NCT02056236 ↗ “Propofol (2,6-diisopropylphenol) is an intravenous anesthetic.” NCT06423846 ↗ “Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium” NCT01584570 ↗ “General anesthesia (standardized induction): Propofol 2 mg/kg” NCT07414706 ↗ “Propofol for Treatment-Resistant Depression: A Pilot Study.” PMID 30260415 ↗ Dec 2018 “Anesthesia will be induced with IV propofol (1.5-2.5 mg/kg)” NCT07485517 ↗ “intravenous administration of fentanyl 2µg/kg and propofol” NCT03600454 ↗ “3 mg/kg of propofol combined with 3 µg/kg of remifentanil” NCT01910285 ↗ “anaesthesia will be induced with 1.5-2.5 mg/kg propofol” NCT07603596 ↗ “Propofol * IV bolus of 0.4 mg/kg for sedation induction” NCT01840371 ↗ “Inducing unconciouness with 1.5 to 2 mg/kg of propofol” NCT03447691 ↗ “anesthesia with propofol 3 milligram/kilogram (mg/kg)” NCT03408340 ↗ “Propofol is the commonest hypnotic agent worldwide.” NCT05166330 ↗ “Intravenous Sedation by Administration of Propofol” NCT04014218 ↗ “Anesthesia maintenance: Propofol TCI: 3-4ug / ml” NCT04805775 ↗ “Light anesthesia with propofol and remifentanil” NCT07479719 ↗ “Propofol 3micrgr/ml (TCI plasma concentration)” NCT01222169 ↗ “utilizing a propofol-remifentanil combination” NCT07123870 ↗ “induced with propofol (1-2mg/kg) or etomidate” NCT01566838 ↗ “intravenous midazolam 2mg, propofol 2mg kg-1” NCT06493396 ↗ “using propofol for maintenance of hypnosis” NCT02839668 ↗ “total intravenous anesthesia with propofol” NCT03094533 ↗ “Anesthesia induction: propofol 1.5-2 mg/kg” NCT05557253 ↗ “sedated with propofol 0.5 - 1.0 mg / kg.” NCT01994070 ↗ “propofol 1.5-2mg/kg (intravenous bolus)” NCT04507165 ↗ “Intravenous hypnotic Propofol 2-5 mg/kg” NCT06271174 ↗ “target controlled infusion of propofol” NCT06024733 ↗ “Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg” NCT04894864 ↗ “propofol 8mg/kg/h saline 0.24 ml/kg/h” NCT01501786 ↗ “2-3mg/kg Propofol (for introduction )” NCT07568938 ↗ “Group "PROP" with 2.2 mg/kg propofol” PMID 31694576 ↗ Nov 2019 “iv induction by propofol 2mg /kg” NCT05825430 ↗ “Propofol 1-3 mg/kg intravenously” NCT01511627 ↗ “Propofol at lowest dosage.” NCT02612363 ↗ “Propofol 2-3mg/kg IV bolus” NCT04081545 ↗ “* Propofol for induction,” NCT07337135 ↗ “IV propofol for sedation” NCT03954379 ↗ “propofol (0.5-2mg / kg)” NCT04063046 ↗ “Target plasma propofol” NCT05885100 ↗ “sevoflurane, propofol” NCT01866657 ↗ “Propofol 1-3 mg/kg IV” NCT04197570 ↗ “Propofol: 1-2mg/Kg iv” NCT07558226 ↗ “Propofol 2-2.5 mg/kg” NCT01474252 ↗ “propofol 4-8 mg/kg/h” NCT05962671 ↗ “propofol 2mg kg-1” NCT06305221 ↗ “propofol” NCT05358535 ↗ “propofol” NCT03094533 ↗ “propofol” NCT02567929 ↗ “Propofol” NCT00767767 ↗ |
| Known as | 2,6-Diisopropylphenol | “Propofol, known chemically as 2, 6-diisopropyl phenol, is an organic compound with the chemical formula C12H18O and is a short-acting intravenous anesthetic used for the...” NCT05606315 ↗6“Propofol (2, 6 - diisopropylphenol), a highly liposoluble anaesthetic, has a potent antioxidant activity against lipid peroxidation in both in vitron and in vivo studies.” NCT01334424 ↗ “Intravenous anesthetic, propofol (2,6-diisopropylphenol), is extensively used for general anesthesia without knowing the effects on cancer.” PMID 12127688 ↗ Oct 2002 “Propofol (2,6-diisopropylphenol) is one of the most common induction and sedative agents used today.” NCT01401049 ↗ “Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous” NCT03844841 ↗ “Propofol (2,6-diisopropylphenol) is an intravenous anesthetic.” NCT06423846 ↗ “Propofol (2,6-diisopropylphenol) is a hypnotic agent” NCT05466279 ↗ |
| Known as | ANESVAN INJECTION 10MG/ML (PROPOFOL) "CHI SHENG" | “ANESVAN INJECTION 10MG/ML (PROPOFOL) "CHI SHENG"” NCT05606692 ↗ |
| Known as | Diprivan | “Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep.” NCT06644573 ↗11“The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).” NCT02659228 ↗ “Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.” NCT01006668 ↗ “0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).” NCT02079090 ↗ “Drug: Propofol Injection [Diprivan]” NCT04291794 ↗ “Diprivan (propofol, Astra Zeneca)” NCT00541918 ↗ “Propofol, Diprivan, Fresenius” NCT01279499 ↗ “Propofol Injection [Diprivan]” NCT04213833 ↗ “ICI35,868 (Diprivan)” NCT01961349 ↗ |
| Known as | Diprivan 2% | “The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models...” NCT01932424 ↗ |
| Known as | Diprivan-Astra Zeneca | “Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.” NCT00757458 ↗ |
| Known as | Diprivant | “Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.” NCT04998253 ↗ |
| Known as | Fresofol | “adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 \~ 50 BIS” NCT02609087 ↗ |
| Known as | Fresofol (2% propofol, Fresinius Kabi) | “Fresofol (2% propofol, Fresinius Kabi)” NCT01826149 ↗ |
| Known as | ICI35,868 | “ICI35,868 (propofol)” NCT01189604 ↗ |
| Known as | Lipid emulsion propofol: Diprivan | “Lipid emulsion propofol: Diprivan®” NCT00908726 ↗ |
| Known as | Microemulsion propofol: AquafolTM | “Microemulsion propofol: AquafolTM” NCT00908726 ↗ |
| Known as | N01AX03 - Propofol | “N01AX03 - Propofol” NCT02651792 ↗ |
| Known as | Pofol | “In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an...” NCT01920113 ↗ |
| Known as | Pro | “Microdialysis probes were implanted in three groups of 10 patients each receiving either sevoflurane (SEVO), propofol (PRO), or spinal (SA) anaesthesia (for induction and maintenance).” PMID 18029344 ↗ Nov 20072“Alfentanil (Alf) is used in combination with Propofol (Pro) in fiber-bronchoscopy and in many other conscious sedation procedures.” NCT01470170 ↗ “Drug: Propofol (PRO)” NCT07556133 ↗ |
| Known as | Propofol (Diprivan) | “Propofol (Diprivan)” NCT07267377 ↗1“Propofol (Diprivan)” NCT07211828 ↗ |
| Known as | propofol (Fresofol(R)2 MCT 2%, Fresenius Kabi) | “propofol (Fresofol(R)2 MCT 2%, Fresenius Kabi)” NCT02191371 ↗ |
| Known as | Propofol 1 % Injectable Suspension | “Drug: Propofol 1 % Injectable Suspension” NCT02953210 ↗ |
| Known as | Propofol 2% (20 mg/mL) MCT Fresenius | “Propofol 2% (20 mg/mL) MCT Fresenius” NCT01856998 ↗ |
| Known as | Propofol = Propofolum = Diprivan = Disoprivan | “Propofol = Propofolum = Diprivan = Disoprivan” NCT01567657 ↗ |
| Known as | Propofol Abbott | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04997707 ↗ |
| Known as | Propofol Fresenius | “Drug: Propofol Fresenius” NCT04872881 ↗1“Drug: Propofol Fresenius” NCT04664595 ↗ |
| Known as | Propofol Injectable Emulsion | “A Randomized, Open-Label, Single-Bolus, 2-Period, Multi-Dose Level, 3 Cohort Crossover Design, Pharmacokinetic/Pharmacodynamic Study of Lusedra (Fospropofol Disodium) Injection...” NCT01260142 ↗ |
| Known as | Propofol injection | “Drug: Propofol injection” NCT06867068 ↗ |
| Known as | Propofol Injection 1% | “Propofol Injection 1%” NCT04164264 ↗ |
| Known as | Propofol Kabi | “Propofol (Propofol Kabi, Registration number from the State Register of Medicines - 000875) is a widely used intravenous anesthetic.” NCT04695509 ↗1“Propofol (1 group (Propofol Kabi, Registration number from the State Register of Medicines - 000875))” NCT05045170 ↗ |
| Known as | Propofol Lipuro | “Propofol Lipuro (Propofol, B-Braun) Fentanyl (Fentanyl, J&J)” NCT02732132 ↗ |
| Known as | Propofol Medium and Long Chain Fat Emulsion Injection | “IV Propofol Medium and Long Chain Fat Emulsion Injection” NCT06222294 ↗ |
| Known as | Propofolum | “Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous” NCT03844841 ↗ |
| Known as | Propoven | “Anaesthesia induction in Group P was performed with propofol (Propoven, Fresenius Kabi) and in Group S with sevoflurane (Sevorane, Abbott Laboratories).” NCT02229201 ↗ |
| Known as | total intravenous anesthesia | “total intravenous anesthesia” NCT05926336 ↗ |
| Action | Activate | “Propofol is known to stimulate gamma - aminobutyric acid- A (GABA-A) receptors by enhancing channel opening” NCT00228267 ↗ |
| Modality | Small molecule | “Propofol (2,6 di-isopropylphenol) is available as an emulsion of 1 % propofol in 10% soyabean oil, 2% glycerol and 1.2% egg phosphatide.” NCT00228267 ↗ |
| Route | Intravenous | “IV propofol sedation” NCT00192959 ↗ |
| Target | NOS2 | “propofol inhibits superoxide formation or downregulates iNOS gene expression in cardiac tissue.” NCT00734383 ↗ |